Inherently radiopaque polymeric products for embolotherapy
View Patent ↗Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.
1. An embolotherapy formulation, comprising polymer particles shaped to embolize a body lumen, the polymer particles being suspended in a pharmaceutically acceptable liquid and having an excluded diameter of from about 10 microns to about 3,000 microns, and comprising polymeric units having a structure according to Formula I:
wherein X=I or Br; Y1 and Y2 independently=0, 1, 2, 3 or 4;
wherein f is between 0 and less than 1, g ranges from 0 to 1, inclusive, and f+g is between 0 and 1, inclusive;
wherein R and R 2 are independently selected from:
wherein for each R 2 , each subgroup R 1 is an H, and, for each R, each subgroup R 1 is independently a long chain aliphatic hydrocarbon;
wherein j and m are independently integers from 1 to 8 inclusive;
wherein Z is independently either O or S;
wherein A is selected from the group consisting of:
wherein R 1 is independently an H or an alkyl group ranging, from 1 to about 18 carbon atoms containing from 0 to 5 heteroatoms selected from O and N; R 3 is a saturated or unsaturated, substituted or unsubstituted alkyl, aryl, or alkylaryl group containing up to about 18 carbon atoms and 0 to 8 heteroatoms selected from O and N; and B is an aliphatic linear or branched diol, or a poly(alkylene glycol) unit.
2. A method of embolizing, a body lumen, comprising introducing into the body lumen an effective amount of the embolotherapy formulation of claim 1 .
3. The method of claim 2 , wherein said introducing is accomplished by injection via either a catheter or syringe.
4. A method of treating varicose and/or spider veins, comprising administering within said varicose and/or spider veins an effective amount of the embolotherapy formulation of claim 1 .
5. The method of claim 4 , wherein said administering is accomplished by injection via either a catheter or syringe.
6. The embolotherapy formulation of claim 1 , wherein Y1 and Y2 are independently 2 or less, and Y1+Y2=1, 2, 3 or 4.
7. The embolotherapy formulation of claim 1 , wherein B is a poly(C1-C4 alkylene glycol) unit and said units are present in a weight fraction of less than about 25 wt %.
8. The embolotherapy formulation of claim 7 , wherein B is a poly(ethylene glycol) unit.
9. The embolotherapy formulation of claim 1 , wherein all X groups are ortho-directed.
10. The embolotherapy formulation of claim 1 , wherein g ranges from greater than 0.1 to about 0.35.
11. The embolotherapy formulation of claim 1 , wherein said formulation comprises polymer particles selected from the group consisting of spherical particles, geometric-ally non-uniform particles, porous particles, hollow particles, solid particles, and particles having an excluded diameter of from about 1.0 microns to about 3,000 microns, and combinations thereof.
12. The embolotherapy formulation of claim 1 , wherein said polymer further comprises an effective amount of at least one therapeutic agent.
13. The embolotherapy formulation of claim 12 , wherein said at least one therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a non-steroidal anti-inflammatory, or a steroidal anti-inflammatory.